Drugs / AZD6553
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01068184 | Feb → May 2010 | chronic obstructive pulmonary disease | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD6553 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01068184 ↗ |
| Action | Inhibit | “AZD6553 acts by reducing the activity of a protease found to be involved in the disease process in COPD.” NCT01068184 ↗ |
| Modality | Small molecule | — CHEMBL6068544 ↗ |
| Route | Oral | “AZD6553 is being developed as a novel oral treatment” NCT01068184 ↗ |